

# Global Intravenous Solutions Market Report and Forecast 2023-2031

Market Report | 2023-04-21 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

## Report description:

Global Intravenous Solutions Market Report and Forecast 2023-2031

Global Intravenous Solutions Market Outlook

The growth of the global intravenous solutions market is being driven by the rising prevalence of the chronic diseases across the globe. The market value was 12.16 billion in 2022 and it is anticipated to grow at a CAGR of 7.15% during the forecast period of 2023-2031. The global intravenous solutions market is anticipated to achieve a value of USD 22.64 billion by 2031.

Intravenous Solutions: Introduction

Intravenous (IV) solutions are sterile fluids that are administered directly into a patient's veins to provide fluids, electrolytes, medications, and nutrients. They are used to treat a variety of medical conditions such as dehydration, electrolyte imbalances, and nutrient deficiencies. IV solutions are also used to deliver medications and other therapies directly into the bloodstream. There are several types of IV solutions available, including crystalloids, colloids, and blood products. Crystalloids are solutions that contain small molecules and are used to replace lost fluids and electrolytes. Colloids, on the other hand, contain larger molecules and are used to maintain blood volume and improve blood flow. Blood products, such as plasma and platelets, are used to treat conditions such as anaemia and bleeding disorders.

IV solutions are typically administered in hospitals, clinics, ambulatory surgical centres, and home care settings. They are administered by healthcare professionals, including nurses and doctors, who are trained in the proper administration of IV therapy.

The global IV solutions market is expected to grow significantly in the coming years due to the increasing incidence of chronic diseases, rising geriatric population, and the growing demand for parenteral nutrition therapy. Key players in the market are focused on developing new and innovative IV solutions and expanding their product portfolios to strengthen their market position. In conclusion, IV solutions are an essential component of modern healthcare and are used to treat a wide range of medical conditions. With the increasing demand for advanced IV solutions and the expanding product portfolios of key players in the market, the global IV solutions market is expected to witness significant growth in the coming years.

Intravenous Solutions: Applications and Uses

Intravenous (IV) solutions have a wide range of applications in healthcare, including:

- Hydration therapy: IV fluids are used to treat dehydration caused by illnesses such as gastroenteritis, heat exhaustion, and kidney disease.
- Therapeutic injections: IV therapy is used to administer medications directly into the bloodstream, allowing for faster and more effective delivery than oral medications.
- Parenteral nutrition: IV solutions are used to provide essential nutrients to patients who are unable to receive adequate nutrition through oral or enteral routes.
- Blood transfusions: IV solutions are used to deliver blood products such as red blood cells, plasma, and platelets to patients who require them.
- Chemotherapy: IV therapy is used to deliver chemotherapy drugs to cancer patients, allowing for targeted delivery and minimizing the risk of side effects.
- Anaesthesia: IV solutions are used to administer anaesthesia during surgeries and medical procedures.
- Electrolyte imbalances: IV solutions are used to restore normal electrolyte balance in patients with conditions such as hyponatremia or hyperkalaemia.
- -¬Shock: IV solutions are used to treat shock caused by trauma, infection, or other medical conditions.

Overall, IV solutions are an essential tool in modern healthcare, providing critical fluids, medications, and nutrients to patients in need. The versatility of IV therapy allows for targeted treatment of a variety of medical conditions, making it an essential component of modern medical practice.

Global Intravenous Solutions Market Segmentations

Market Breakup by Type

- -□Partial Parenteral Nutrition
- -∏Total Parenteral Nutrition

#### Market Breakup by Nutrients

- -□Market Overview
- Carbohydrates
- -□Salts and Electrolytes
- -□Minerals
- -∏Vitamins
- -□Amino Acids

## Market Breakup by Bag Type

- Large Volume Bags (>250 mL)
- -∏Small Volume Bags (<250 mL)

## Market Breakup by Application

- -□Basic IV Solution
- Nutritional IV Solution
- -∏Blood IV Solution
- -□Drug IV Solution
- Irrigation IV Solution

## Market Breakup by End User

- -□Hospitals
- -□Clinics
- Ambulatory Surgical Centre

Scotts International, EU Vat number: PL 6772247784

- Homecare Settings
- -[Others

Market Breakup by Region

- North America
- United States of America
- -[Canada
- -∏Europe
- United Kingdom
- -[]Germany
- -∏France
- -∏Italy
- -∏Others
- -∏Asia Pacific
- -□China
- -∏apan
- -□India
- -∏ASEAN
- -□Australia
- Others
- -∏Latin America
- -∏Brazil
- -[]Argentina
- -∏Mexico
- Others
- Middle East and Africa
- -∏Saudi Arabia
- -□United Arab Emirates
- -□Nigeria
- -□South Africa
- -∏Others

#### Global Intravenous Solutions Market Scenario

The global intravenous (IV) solutions market is expected to grow significantly in the coming years, driven by factors such as the increasing incidence of chronic diseases, rising geriatric population, and the growing demand for parenteral nutrition therapy. Crystalloids are the most commonly used type of IV solutions and are expected to continue to dominate the market during the forecast period. However, colloids are also expected to gain traction due to their advantages over crystalloids in certain applications.

The hydration therapy application segment is expected to hold the largest share of the market, driven by the increasing incidence of dehydration and the growing demand for fluid replacement therapy. The nutrition support application segment is also expected to grow significantly due to the rising prevalence of malnutrition and the increasing use of parenteral nutrition therapy. Geographically, the market is expected to experience significant growth in North America and Europe due to the presence of well-established healthcare infrastructure and a growing demand for advanced IV solutions. However, the Asia Pacific region is expected to witness the highest growth rate due to the increasing incidence of chronic diseases and the growing geriatric population in the region.

In conclusion, the global IV solutions market is expected to witness significant growth in the coming years due to the increasing incidence of chronic diseases, rising geriatric population, and the growing demand for parenteral nutrition therapy. The market is

Scotts International, EU Vat number: PL 6772247784

expected to be driven by factors such as the expanding product portfolios of key players in the market, the increasing demand for advanced IV solutions, and the growing awareness about the benefits of IV therapy among healthcare professionals and patients. Key Players in the Global Intravenous Solutions Market

The report gives an in-depth analysis of the key players involved in the global intravenous solutions market. The companies included in the market are as follows:

- Ajinomoto Health & Nutrition North America, Inc.
- -□B. Braun Medical Inc.
- -∏ICU Medical, Inc.
- -□Baxter International, Inc.
- Fresenius Kabi AG
- -□Pfizer inc.
- -□Otsuka Pharmaceutical Co., Ltd.
- -□Vifor Pharma Management Ltd.
- -□JW Life Science
- -∏Amanta Healthcare
- -□Grifols, S.A.

#### **Table of Contents:**

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Intravenous Solutions Market Overview
  - 3.1 Global Intravenous Solutions Market Historical Value (2016-2022)
  - 3.2 Global Intravenous Solutions Market Forecast Value (2023-2031)
- 4 Global Intravenous Solutions Market Landscape
  - 4.1 Global Intravenous Solutions Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Intravenous Solutions Product Landscape
    - 4.2.1 Analysis by Type
    - 4.2.2 Analysis by Nutrients
    - 4.2.3 Analysis by Bag Type
    - 4.2.4 Analysis by Applications
    - 4.2.5 Analysis by End User
- 5 Global Intravenous Solutions Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model

Scotts International. EU Vat number: PL 6772247784

- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Intravenous Solutions Market Segmentation
  - 6.1 Global Intravenous Solutions Market by Type
    - 6.1.1 Market Overview
    - 6.1.2 Partial Parenteral Nutrition
    - 6.1.3 Total Parenteral Nutrition
  - 6.2 Global Intravenous Solutions Market by Nutrients
    - 6.2.1 Market Overview
    - 6.2.2 Carbohydrates
    - 6.2.3 Salts and Electrolytes
    - 6.2.4 Minerals
    - 6.2.5 Vitamins
    - 6.2.6 Amino Acids
  - 6.3 Global Intravenous Solutions Market by Bag Type
    - 6.3.1 Market Overview
    - 6.3.2 Large Volume Bags (>250 mL)
    - 6.3.3 Small Volume Bags (<250 mL)
  - 6.4 Global Intravenous Solutions Market by Application
    - 6.4.1 Market Overview
    - 6.4.2 Basic IV Solution
    - 6.4.3 Nutritional IV Solution
    - 6.4.4 Blood IV Solution
    - 6.4.5 Drug IV Solution
    - 6.4.6 Irrigation IV Solution
  - 6.5 Global Intravenous Solutions Market by End User
    - 6.5.1 Market Overview
    - 6.5.2 Hospitals
    - 6.5.3 Clinics
    - 6.5.4 Ambulatory Surgical Centres
    - 6.5.5 Homecare Settings
    - 6.5.6 Others
  - 6.6 Global Intravenous Solutions Market by Region
    - 6.6.1 Market Overview
    - 6.6.2 North America
    - 6.6.3 Europe
    - 6.6.4 Asia Pacific
    - 6.6.5 Latin America
    - 6.6.6 Middle East and Africa
- 7 North America Intravenous Solutions Market
  - 7.1 Market Share by Country
  - 7.2 United States of America
  - 7.3 Canada
- 8 Europe Intravenous Solutions Market
  - 8.1 Market Share by Country

Scotts International. EU Vat number: PL 6772247784

- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Intravenous Solutions Market
  - 9.1 Market Share by Country
  - 9.2 China
  - 9.3 Japan
  - 9.4 India
  - 9.5 ASEAN
  - 9.6 Australia
  - 9.7 Others
- 10 Latin America Intravenous Solutions Market
  - 10.1 Market Share by Country
  - 10.2 Brazil
  - 10.3 Argentina
  - 10.4 Mexico
  - 10.5 Others
- 11 Middle East and Africa Intravenous Solutions Market
  - 11.1 Market Share by Country
  - 11.2 Saudi Arabia
  - 11.3 United Arab Emirates
  - 11.4 Nigeria
  - 11.5 South Africa
  - 11.6 Others
- 12 Patent Analysis
  - 12.1 Analysis by Type of Patent
  - 12.2 Analysis by Publication Year
  - 12.3 Analysis by Issuing Authority
  - 12.4 Analysis by Patent Age
  - 12.5 Analysis by CPC Analysis
  - 12.6 Analysis by Patent Valuation
  - 12.7 Analysis by Key Players
- 13 Grants Analysis
  - 13.1 Analysis by year
  - 13.2 Analysis by Amount Awarded
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Grant Application
  - 13.5 Analysis by Funding Institute
  - 13.6 Analysis by NIH Departments
  - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
  - 14.1 Analysis by Funding Instances
  - 14.2 Analysis by Type of Funding
  - 14.3 Analysis by Funding Amount
  - 14.4 Analysis by Leading Players

Scotts International. EU Vat number: PL 6772247784

- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
  - 15.1 Analysis by Partnership Instances
  - 15.2 Analysis by Type of Partnership
  - 15.3 Analysis by Leading Players
  - 15.4 Analysis by Geography
- 16 Regulatory Framework
  - 16.1 Regulatory Overview
    - 16.1.1 US FDA
    - 16.1.2 EU EMA
    - 16.1.3 INDIA CDSCO
    - 16.1.4 JAPAN PMDA
    - 16.1.5 Others
- 17 Supplier Landscape
  - 17.1 Ajinomoto Health & Nutrition North America, Inc.
    - 17.1.1 Financial Analysis
    - 17.1.2 Product Portfolio
    - 17.1.3 Demographic Reach and Achievements
    - 17.1.4 Mergers and Acquisitions
    - 17.1.5 Certifications
  - 17.2 B. Braun Medical Inc.
    - 17.2.1 Financial Analysis
    - 17.2.2 Product Portfolio
    - 17.2.3 Demographic Reach and Achievements
    - 17.2.4 Mergers and Acquisitions
    - 17.2.5 Certifications
  - 17.3 ICU Medical, Inc.
    - 17.3.1 Financial Analysis
    - 17.3.2 Product Portfolio
    - 17.3.3 Demographic Reach and Achievements
    - 17.3.4 Mergers and Acquisitions
    - 17.3.5 Certifications
  - 17.4 Baxter International, Inc.
    - 17.4.1 Financial Analysis
    - 17.4.2 Financial Portfolio
    - 17.4.3 Demographic Reach and Achievements
    - 17.4.4 Mergers and Acquisitions
    - 17.4.5 Certifications
  - 17.5 Fresenius Kabi AG
    - 17.5.1 Financial Analysis
    - 17.5.2 Product Portfolio
    - 17.5.3 Demographic Reach and Achievements
    - 17.5.4 Mergers and Acquisitions
    - 17.5.5 Certifications
  - 17.6 Pfizer inc.
    - 17.6.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Otsuka Pharmaceutical Co., Ltd.
  - 17.7.1 Financial Analysis
  - 17.7.2 Product Portfolio
  - 17.7.3 Demographic Reach and Achievements
  - 17.7.4 Mergers and Acquisitions
  - 17.7.5 Certifications
- 17.8 Vifor Pharma Management Ltd.
  - 17.8.1 Financial Analysis
  - 17.8.2 Product Portfolio
  - 17.8.3 Demographic Reach and Achievements
  - 17.8.4 Mergers and Acquisitions
  - 17.8.5 Certifications
- 17.9 IW Life Science
  - 17.9.1 Financial Analysis
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisitions
  - 17.9.5 Certifications
- 17.10 Amanta Healthcare
  - 17.10.1 Financial Analysis
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisitions
  - 17.10.5 Certifications
- 17.11 Grifols, S.A.
  - 17.11.1 Financial Analysis
  - 17.11.2 Product Portfolio
  - 17.11.3 Demographic Reach and Achievements
  - 17.11.4 Mergers and Acquisitions
  - 17.11.5 Certifications
- 18 Global Intravenous Solutions Market Distribution Model (Additional Insight)
  - 18.1 Overview
  - 18.2 Potential Distributors
  - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
  - 20.1 Very Small Companies
  - 20.2 Small Companies
  - 20.3 Mid-Sized Companies
  - 20.4 Large Companies
  - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
  - 21.1 Government Funded

Scotts International, EU Vat number: PL 6772247784

- 21.2 Private Insurance
- 21.3 Out-of-Pocket



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$  - Complete the relevant blank fields and sign

# Global Intravenous Solutions Market Report and Forecast 2023-2031

Market Report | 2023-04-21 | 147 pages | EMR Inc.

ORDER FORM:						1
Select license	License					Price
	Single User License				\$5999.00	
	Five User License				\$7999.00	
	Corporate License				\$9999.00	
					VAT Total	
Please circle the rel	evant license option. For an	ny questions plea	ase contact support@	scotts-international.c	com or 0048 603 3	94 346.
	evant license option. For and at 23% for Polish based co					
** VAT will be adde						
** VAT will be adde Email*			duals and EU based o			
** VAT will be adde Email* First Name*			duals and EU based of Phone*			
** VAT will be adde Email* First Name* Ob title*			duals and EU based of Phone*	companies who are u		
]** VAT will be adde Email* First Name* ob title* Company Name*			duals and EU based of Phone*  Last Name*	companies who are u		
I** VAT will be adde Email* First Name* ob title* Company Name* Address*			Phone*  Last Name*  EU Vat / Tax ID /	companies who are u		
			Phone* Last Name*  EU Vat / Tax ID / City*	companies who are u		

Scotts International. EU Vat number: PL 6772247784